{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T11:27:06Z","timestamp":1789990026432,"version":"4.0.1"},"reference-count":50,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["cancerletters.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1016\/j.canlet.2015.03.009","type":"journal-article","created":{"date-parts":[[2015,3,26]],"date-time":"2015-03-26T15:42:22Z","timestamp":1427384542000},"page":"25-35","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Selective targeting of FAK\u2013Pyk2 axis by alpha-naphthoflavone abrogates doxorubicin resistance in breast cancer cells"],"prefix":"10.1016","volume":"362","author":[{"given":"Amrita","family":"Datta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobel","family":"Bhasin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hogyoung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish","family":"Ranjan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Rider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zakaria Y.","family":"Abd Elmageed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debasis","family":"Mondal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishna C.","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asim B.","family":"Abdel-Mageed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2015.03.009_bib0010","unstructured":"National Cancer Institute at the National Institute of Health (http:\/\/www.cancer.gov\/) and Breastcancer.org group (http:\/\/www.breastcancer.org\/)."},{"key":"10.1016\/j.canlet.2015.03.009_bib0015","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1124\/pr.56.2.6","article-title":"Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity","volume":"56","author":"Minotti","year":"2004","journal-title":"Pharmacol. Rev"},{"key":"10.1016\/j.canlet.2015.03.009_bib0020","series-title":"Cancer Chemotherapy Basic and Clinical Pharmacology","author":"Katzung","year":"2006"},{"key":"10.1016\/j.canlet.2015.03.009_bib0025","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0006-2952(98)00307-4","article-title":"A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin","volume":"57","author":"Gewirtz","year":"1999","journal-title":"Biochem. Pharmacol"},{"key":"10.1016\/j.canlet.2015.03.009_bib0030","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s12012-007-0015-3","article-title":"Role of anthracyclines in the era of targeted therapy","volume":"7","author":"Cortes-Funes","year":"2007","journal-title":"Cardiovasc. Toxicol"},{"key":"10.1016\/j.canlet.2015.03.009_bib0035","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1021\/cr9000226","article-title":"ABC efflux pump-based resistance to chemotherapy drugs","volume":"109","author":"Eckford","year":"2009","journal-title":"Chem. Rev"},{"key":"10.1016\/j.canlet.2015.03.009_bib0040","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrd1984","article-title":"Targeting multidrug resistance in cancer","volume":"5","author":"Szakacs","year":"2006","journal-title":"Nat. Rev. Drug Discov"},{"key":"10.1016\/j.canlet.2015.03.009_bib0045","first-page":"F37","article-title":"P-glycoprotein multidrug resistance and cancer","volume":"1288","author":"Bosch","year":"1996","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.canlet.2015.03.009_bib0050","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/978-1-60761-416-6_15","article-title":"Overcoming multidrug resistance in cancer: clinical studies of p-glycoprotein inhibitors","volume":"596","author":"Coley","year":"2010","journal-title":"Methods Mol. Biol"},{"key":"10.1016\/j.canlet.2015.03.009_bib0055","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1146\/annurev.bi.62.070193.002125","article-title":"Biochemistry of multidrug resistance mediated by the multidrug transporter","volume":"62","author":"Gottesman","year":"1993","journal-title":"Annu. Rev. Biochem"},{"key":"10.1016\/j.canlet.2015.03.009_bib0060","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/1477-7819-3-61","article-title":"Role of p-glycoprotein expression in predicting response to neoadjuvant chemotherapy in breast cancer \u2013 a prospective clinical study","volume":"3","author":"Chintamani","year":"2005","journal-title":"World J. Surg. Oncol"},{"key":"10.1016\/j.canlet.2015.03.009_bib0065","first-page":"827","article-title":"RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response","volume":"9","author":"Burger","year":"2003","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.canlet.2015.03.009_bib0070","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.ejps.2005.11.002","article-title":"The role of transporters in drug interactions","volume":"27","author":"Endres","year":"2006","journal-title":"Eur. J. Pharm. Sci"},{"key":"10.1016\/j.canlet.2015.03.009_bib0075","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1080\/21551197.2012.702534","article-title":"Flavonoids and cancer prevention: a review of the evidence","volume":"31","author":"Romagnolo","year":"2012","journal-title":"J. Nutr. Gerontol. Geriatr"},{"key":"10.1016\/j.canlet.2015.03.009_bib0080","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S0024-3205(99)00120-4","article-title":"Flavonoids: old and new aspects of a class of natural therapeutic drugs","volume":"65","author":"Di Carlo","year":"1999","journal-title":"Life Sci"},{"key":"10.1016\/j.canlet.2015.03.009_bib0085","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/0006-2952(83)90262-9","article-title":"A class of natural products of high pharmacological potency","volume":"32","author":"Havsteen","year":"1983","journal-title":"Biochem. Pharmacol"},{"key":"10.1016\/j.canlet.2015.03.009_bib0090","first-page":"25","article-title":"A review of phytochemistry and pharmacology of flavonoids","volume":"1","author":"Sandhar","year":"2011","journal-title":"Int. Pharmacol. Sci"},{"key":"10.1016\/j.canlet.2015.03.009_bib0095","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.bcp.2005.05.017","article-title":"Structure activity relationships and quantitative structure activity relationships for the flavonoid-mediated inhibition of breast cancer resistance protein","volume":"70","author":"Zhang","year":"2005","journal-title":"Biochem. Pharmacol"},{"key":"10.1016\/j.canlet.2015.03.009_bib0100","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1124\/mol.65.5.1208","article-title":"Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport","volume":"65","author":"Zhang","year":"2004","journal-title":"Mol. Pharmacol"},{"key":"10.1016\/j.canlet.2015.03.009_bib0105","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1007\/s12012-007-0018-0","article-title":"Protection by flavonoids against anthracycline cardiotoxicity: from chemistry to clinical trials","volume":"7","author":"Bast","year":"2007","journal-title":"Cardiovasc. Toxicol"},{"key":"10.1016\/j.canlet.2015.03.009_bib0110","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s10565-006-0139-4","article-title":"Protectors against doxorubicin-induced cardiotoxicity: flavonoids","volume":"23","author":"Bast","year":"2007","journal-title":"Cell Biol. Toxicol"},{"key":"10.1016\/j.canlet.2015.03.009_bib0115","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1007\/s11064-009-9969-9","article-title":"The flavonoid glycosides, myricitrin, gossypin and naringin exert anxiolytic action in mice","volume":"34","author":"Fernandez","year":"2009","journal-title":"Neurochem. Res"},{"key":"10.1016\/j.canlet.2015.03.009_bib0120","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1093\/carcin\/7.7.1187","article-title":"Inhibition of the prenatal dimethylbenz(a)anthracene-induced tumour initiation in mice by prior administration of 7,8-benzoflavone","volume":"7","author":"Goerttler","year":"1986","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.canlet.2015.03.009_bib0125","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1093\/carcin\/3.7.791","article-title":"Tumor initiation by 7,12-dimethylbenz(a)anthracene in dermal melanocytes of hamster: inhibition through 7,8-benzoflavone","volume":"3","author":"Goerttler","year":"1982","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.canlet.2015.03.009_bib0130","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1021\/tx980090+","article-title":"Selectivity of polycyclic inhibitors for human cytochrome P450s 1A1, 1A2, and 1B1","volume":"11","author":"Shimada","year":"1998","journal-title":"Chem. Res. Toxicol"},{"key":"10.1016\/j.canlet.2015.03.009_bib0135","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1074\/jbc.272.6.3149","article-title":"Differential mechanisms of cytochrome P450 inhibition and activation by alpha-naphthoflavone","volume":"272","author":"Koley","year":"1997","journal-title":"J. Biol. Chem"},{"key":"10.1016\/j.canlet.2015.03.009_bib0140","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1016\/j.bmc.2007.10.057","article-title":"New 7,8-benzoflavanones as potent aromatase inhibitors: synthesis and biological evaluation","volume":"16","author":"Yahiaoui","year":"2008","journal-title":"Bioorg. Med. Chem"},{"key":"10.1016\/j.canlet.2015.03.009_bib0145","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1126\/science.6474163","article-title":"Inhibition of human estrogen synthetase (aromatase) by flavones","volume":"225","author":"Kellis","year":"1984","journal-title":"Science"},{"key":"10.1016\/j.canlet.2015.03.009_bib0150","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1289\/ehp.6322","article-title":"Flavonoids as aryl hydrocarbon receptor agonists\/antagonists: effects of structure and cell context","volume":"111","author":"Zhang","year":"2003","journal-title":"Environ. Health Perspect"},{"key":"10.1016\/j.canlet.2015.03.009_bib0155","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1615\/CritRevEukarGeneExpr.v18.i4.10","article-title":"Expression and activity of aryl hydrocarbon receptors in development and cancer","volume":"18","author":"Gasiewicz","year":"2008","journal-title":"Crit. Rev. Eukaryot. Gene Expr"},{"key":"10.1016\/j.canlet.2015.03.009_bib0160","first-page":"1","article-title":"Measurement of apoptosis by DNA fragmentation","volume":"282","author":"Matassov","year":"2004","journal-title":"Methods Mol. Biol"},{"issue":"23","key":"10.1016\/j.canlet.2015.03.009_bib0165","doi-asserted-by":"crossref","first-page":"7994","DOI":"10.1158\/1078-0432.CCR-04-1087","article-title":"Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, isobologram, and combination index analyses","volume":"10","author":"Zhao","year":"2004","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.canlet.2015.03.009_bib0170","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2741\/e86","article-title":"Comparison of methods for evaluating drug-drug interaction","volume":"2","author":"Zhao","year":"2010","journal-title":"Front. Biosci. (Elite Ed)"},{"key":"10.1016\/j.canlet.2015.03.009_bib0175","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1093\/carcin\/bgp093","article-title":"Vitamin C and alpha-naphthoflavone prevent estrogen-induced mammary tumors and decrease oxidative stress in female ACI rats","volume":"30","author":"Mense","year":"2009","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.canlet.2015.03.009_bib0180","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/bjc.1995.133","article-title":"Inhibition of N-linked glycosylation of P-glycoprotein by tunicamycin results in a reduced multidrug resistance phenotype","volume":"71","author":"Kramer","year":"1995","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2015.03.009_bib0185","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1242\/jcs.00373","article-title":"Focal adhesion kinase: the first ten years","volume":"116","author":"Parsons","year":"2003","journal-title":"J. Cell Sci"},{"key":"10.1016\/j.canlet.2015.03.009_bib0190","doi-asserted-by":"crossref","first-page":"629","DOI":"10.2174\/156800905774932798","article-title":"Mechanisms of focal adhesion kinase regulation","volume":"5","author":"Cohen","year":"2005","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.canlet.2015.03.009_bib0195","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1242\/jcs.110.4.401","article-title":"Focal adhesion kinase: at the crossroads of signal transduction","volume":"110","author":"Ilic","year":"1997","journal-title":"J. Cell Sci"},{"key":"10.1016\/j.canlet.2015.03.009_bib0200","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/nrm1549","article-title":"Focal adhesion kinase: in command and control of cell motility","volume":"6","author":"Mitra","year":"2005","journal-title":"Nat. Rev. Mol. Cell Biol"},{"key":"10.1016\/j.canlet.2015.03.009_bib0205","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1242\/jcs.045112","article-title":"Cellular functions of FAK kinases: insight into molecular mechanisms and novel functions","volume":"123","author":"Schaller","year":"2010","journal-title":"J. Cell Sci"},{"key":"10.1016\/j.canlet.2015.03.009_bib0210","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1517\/13543784.2010.489548","article-title":"Therapeutic potential and limitations of new FAK inhibitors in the treatment of cancer","volume":"19","author":"Schultze","year":"2010","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.canlet.2015.03.009_bib0215","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1097\/00005537-200311000-00017","article-title":"Expression of focal adhesion kinase and phosphorylated focal adhesion kinase in squamous cell carcinoma of the larynx","volume":"113","author":"Aronsohn","year":"2003","journal-title":"Laryngoscope"},{"key":"10.1016\/j.canlet.2015.03.009_bib0220","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1046\/j.1525-1438.2003.13396.x","article-title":"The expression and tyrosine phosphorylation of E-cadherin\/catenin adhesion complex, and focal adhesion kinase in invasive cervical carcinomas","volume":"13","author":"Moon","year":"2003","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.canlet.2015.03.009_bib0225","doi-asserted-by":"crossref","first-page":"5933","DOI":"10.1093\/emboj\/17.20.5933","article-title":"Pyk2 and Src-family protein-tyrosine kinases compensate for the loss of FAK in fibronectin-stimulated signaling events but Pyk2 does not fully function to enhance FAK- cell migration","volume":"17","author":"Sieg","year":"1998","journal-title":"EMBO J."},{"key":"10.1016\/j.canlet.2015.03.009_bib0230","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1083\/jcb.200710038","article-title":"Compensatory role for Pyk2 during angiogenesis in adult mice lacking endothelial cell FAK","volume":"181","author":"Weis","year":"2008","journal-title":"J. Cell Biol"},{"key":"10.1016\/j.canlet.2015.03.009_bib0235","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1517\/14728220903473194","article-title":"Targeting Pyk2 for therapeutic intervention","volume":"14","author":"Lipinski","year":"2010","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.canlet.2015.03.009_bib0240","doi-asserted-by":"crossref","first-page":"18573","DOI":"10.1074\/jbc.M110.200717","article-title":"Compensatory function of Pyk2 protein in the promotion of focal adhesion kinase (FAK)-null mammary cancer stem cell tumorigenicity and metastatic activity","volume":"286","author":"Fan","year":"2011","journal-title":"J. Biol. Chem"},{"key":"10.1016\/j.canlet.2015.03.009_bib0245","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s11130-004-0049-7","article-title":"Flavonoids in food and their health benefits","volume":"59","author":"Yao","year":"2004","journal-title":"Plant Foods Hum. Nutr"},{"key":"10.1016\/j.canlet.2015.03.009_bib0250","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1158\/1535-7163.MCT-13-0225-T","article-title":"Phosphoproteomic profiling identifies focal adhesion kinase as a mediator of docetaxel resistance in castrate-resistant prostate cancer","volume":"13","author":"Lee","year":"2014","journal-title":"Mol. Cancer Ther"},{"key":"10.1016\/j.canlet.2015.03.009_bib0255","first-page":"935","article-title":"End points in cancer clinical trials and the drug approval process","volume":"8","author":"Schilsky","year":"2002","journal-title":"Clin. Cancer Res"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383515001895?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383515001895?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T21:58:18Z","timestamp":1651615098000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383515001895"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["S0304383515001895"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2015.03.009","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Selective targeting of FAK\u2013Pyk2 axis by alpha-naphthoflavone abrogates doxorubicin resistance in breast cancer cells","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2015.03.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}